SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26669
Abstract: Patients with B‐cell malignancies have suboptimal immune responses to SARS‐CoV‐2 vaccination and are a high‐risk population for severe COVID19 disease. We evaluated the effect of a third booster BNT162b2 vaccine on the kinetics of anti‐… read more here.
Keywords: patients cell; booster bnt162b2; cell malignancies; humoral responses ... See more keywords
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04221-0
Abstract: The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is… read more here.
Keywords: bispecific cell; cell malignancies; immuno oncology; cell engager ... See more keywords
Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06515-7
Abstract: Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, is crucial for the development of B-cell malignancies. Covalent BTK inhibitors (cBTKis), such as ibrutinib, have demonstrated remarkable efficacy, but their curative potential is… read more here.
Keywords: next generation; tyrosine kinase; cell; bruton tyrosine ... See more keywords
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
Sign Up to like & getrecommendations! Published in 2025 at "Targeted Oncology"
DOI: 10.1007/s11523-025-01133-9
Abstract: Standard treatment options for B cell malignancies include immunochemotherapies and/or targeted therapies, which often provide temporary disease remission. However, many patients do not achieve complete remission with these treatments, develop resistance, and eventually experience disease… read more here.
Keywords: immunomodulatory potential; cell; potential ibrutinib; leveraging immunomodulatory ... See more keywords
"Monocytes in B-Cell Malignancies: Their Role in Disease Progression and Therapy Resistance".
Sign Up to like & getrecommendations! Published in 2025 at "Current oncology reports"
DOI: 10.1007/s11912-025-01732-9
Abstract: Although current treatments have improved outcomes in B-cell malignancies, therapy resistance remains a major challenge and is often driven by the tumor microenvironment. The purpose of this review was to assess the roles of monocytes… read more here.
Keywords: monocyte derived; therapy resistance; monocytes cell; cell malignancies ... See more keywords
Senescent/Exhausted Phenotype of CAR T Cells and Induction of Immunoregulatory Environment Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.394
Abstract: Chimeric antigen receptor (CAR) T cells have shown promising results in patients (pts) with B cell malignancies, yet approximately 60% of pts with diffuse large B cell lymphoma (DLBCL) will relapse. Therefore, future efforts are… read more here.
Keywords: relapsed refractory; response; cell malignancies; car cells ... See more keywords
Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00530
Abstract: Phosphoinositide 3-kinase δ (PI3Kδ) plays a critical role in B lymphocyte (B-cell) development and activation and has been a validated target for the treatment of B-cell malignancies. Herein, we report a series of thienopyrimidine derivatives… read more here.
Keywords: pi3k; cell; treatment cell; thienopyrimidine derivatives ... See more keywords
Discovery of TQ-3959 as a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.5c00956
Abstract: BTK is a critical nonreceptor tyrosine kinase involved in BCR signaling and represents a validated target for treating B-cell malignancies and autoimmune diseases. Although several BTK inhibitors have been approved, their clinical application is limited… read more here.
Keywords: btk; novel benzisoxazole; cell; incorporating novel ... See more keywords
Safe CAR-T: shedding light on CAR-related T-cell malignancies
Sign Up to like & getrecommendations! Published in 2025 at "EMBO Molecular Medicine"
DOI: 10.1038/s44321-025-00205-7
Abstract: As of September 30, 2023, the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database has received 12 reports of secondary T-cell malignancies since the first of the BCMA-/CD19-targeted autologous CAR-T therapies was… read more here.
Keywords: car; cell; shedding light; safe car ... See more keywords
Engineering TAG-72 and CD30 CAR-T Cells for T Cell Malignancies
Sign Up to like & getrecommendations! Published in 2025 at "Immunological Investigations"
DOI: 10.1080/08820139.2025.2538049
Abstract: ABSTRACT Background T cell malignancies represent a broad, highly heterogeneous subset of lymphomas with poor prognosis. Chimeric antigen receptor (CAR)-T cell therapy holds great promise in treating B cell lymphoma and multiple myeloma. However, understanding… read more here.
Keywords: tag cd30; car; cell; tumor ... See more keywords
Mouse Models in the Study of Mature B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Cold Spring Harbor perspectives in medicine"
DOI: 10.1101/cshperspect.a034827
Abstract: Over the past two decades, genomic analyses of several B-cell lymphoma entities have identified a large number of genes that are recurrently mutated, suggesting that their aberrant function promotes lymphomagenesis. For many of those genes,… read more here.
Keywords: mouse models; cell malignancies; mature cell; cell ... See more keywords